MedTrace Logo

Use of Omega-3 Fatty Acids for Perinatal Depression

NCT00402389 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2013-03-29

No results posted yet for this study

Summary

This study will evaluate the effectiveness of using omega-3 fatty acids to treat women with perinatal depression.

Conditions

Interventions

DRUG

Omega-3 Fatty Acids (EPA plus DHA)

Four capsules will be taken daily for 8 weeks.

BEHAVIORAL

Supportive psychotherapy

Supportive psychotherapy will provide education to increase understanding of the condition, guidance on how to cope with depression, and methods on how to improve self-esteem.

DRUG

Placebo

Four capsules will be taken daily for 8 weeks.

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • University of Arizona

    lead OTHER

Principal Investigators

  • Marlene P. Freeman, MD · University of Arizona; Department of Psychiatry

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Primary Completion
2006-01-31
Completion
2006-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00402389 on ClinicalTrials.gov